Amyris, Inc. (NASDAQ:AMRS) Files An 8-K Regulation FD Disclosure

Amyris, Inc. (NASDAQ:AMRS) Files An 8-K Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure.

Investor Presentation
On March 16, 2020, Amyris, Inc. (the “Company”) will be holding virtual individual investor meetings due to the cancellation of the 32nd Annual Roth Conference because of COVID-19. During the virtual meetings, representatives of the Company will present the presentation filed as Exhibit 99.1>to this Current Report on Form 8-K (the “Investor Presentation”). The Investor Presentation will also be posted on the Investor Relations section of the Company\’s website,
By filing this Current Report on Form 8-K and furnishing the information contained herein, the Company makes no admission as to the materiality of any information in this Current Report on Form 8-K that is required to be disclosed solely by reason of Regulation FD.
The information contained in the Investor Presentation is summary information that is intended to be considered in the context of the Company’s filings with the Securities and Exchange Commission (“SEC”) and other public announcements that the Company may make, by press release or otherwise, from time to time. The Company undertakes no duty or obligation to publicly update or revise the information contained in this Current Report on Form 8-K, although it may do so from time to time as its management believes is warranted or as required by applicable law. Any such updating may be made through the filing of other reports or documents with the SEC, through press releases or through other public disclosure.
Press Release
On March 16, 2020, the Company also issued a press release entitled “Amyris Provides Business Update,” a copy of which is furnished as Exhibit 99.2>to this Current Report on Form 8-K and is incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
The following exhibit is furnished herewith:
The information in this report, including the exhibit hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing, unless expressly incorporated by specific reference in such filing.
AMYRIS, INC. Exhibit
EX-99.1 2 ex99103162020.htm EXHIBIT 99.1 ex99103162020 Amyris,…
To view the full exhibit click here

Story continues below

About Amyris, Inc. (NASDAQ:AMRS)

Amyris, Inc. is an integrated industrial biotechnology company. The Company is engaged in research and development and sales of fuels and farnesene-derived products. It is applying its industrial synthetic biology platform to engineer, manufacture and sell products into a range of consumer and industrial markets, including cosmetics, flavors and fragrances (F&F), solvents and cleaners, polymers, lubricants, healthcare products and fuels. The Company focuses on a renewable hydrocarbon molecule called farnesene (Biofene). The Company is expanding its range of products across various categories divided into consumer and industrial applications. For consumer applications, the Company is developing and selling personal care products (which include ingredients for cosmetics and F&F), healthcare products and formulated end user products, such as Biossance brand skincare products and Muck Daddy brand hand cleaner product.

An ad to help with our costs